Laurent Chesnel received his undergraduate degree in Biochemistry from the University of Paris (Paris 6, Sorbonne University), going on to earn his Ph.D. in Structural Microbiology from the Structural Biology Institute, University of Grenoble (2003). Subsequently he conducted his post-doctoral research in cellular microbiology in the Department of Microbial Pathogenesis at the Yale University Medical School (2003-2008). Laurent joined the clinical microbiology group at Cubist Pharmaceuticals in the spring of 2008 where he supported late-stage discovery programs, their transitions into the IND-enabling stage, and clinical trials from Phase 1 to Phase 4 (including surotomycin and fidaxomicin programs). Laurent joined the Merck Research Laboratories Scientific Affairs group in 2015 where he supported external clinical research and scientific engagement (including Bezlotoxumab program) with the academic research community.
In January 2018, Laurent joined Artugen Therapeutics. Laurent is Vice President of Research and Development, leading the company’s transition to clinic.